Brokerages Set Septerna, Inc. (NASDAQ:SEPN) PT at $45.89

Shares of Septerna, Inc. (NASDAQ:SEPN) have received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $45.8889.

A number of equities analysts recently commented on SEPN shares. Guggenheim reduced their price target on Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a report on Wednesday, July 1st. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Septerna in a research note on Wednesday, July 1st. Wall Street Zen downgraded Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Stifel Nicolaus began coverage on shares of Septerna in a report on Friday, May 1st. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their target price on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th.

Septerna Trading Up 4.0%

Shares of SEPN opened at $37.84 on Friday. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -46.72 and a beta of 2.29. Septerna has a 1-year low of $10.62 and a 1-year high of $38.04. The company’s fifty day simple moving average is $30.95 and its 200 day simple moving average is $27.89.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, research analysts forecast that Septerna will post -1.59 earnings per share for the current year.

Insider Transactions at Septerna

In related news, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares in the company, valued at $4,240,247.06. The trade was a 2.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Daniel D. Long sold 3,333 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $34.36, for a total value of $114,521.88. Following the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,312,716.32. The trade was a 3.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 48,494 shares of company stock worth $1,566,751 over the last quarter. Company insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

Hedge funds have recently bought and sold shares of the business. Group One Trading LLC boosted its holdings in Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the period. Global Retirement Partners LLC bought a new stake in shares of Septerna in the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. acquired a new stake in Septerna during the third quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new position in Septerna during the 4th quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Septerna in the 4th quarter valued at $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.